NCT04996030 - A Study for Oral SY-2101 for Participants With Acute Promyelocytic Leukemia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 17, 2021

Primary Completion Date

January 3, 2024

Study Completion Date

April 30, 2024

Conditions

Acute Promyelocytic Leukemia

Interventions

DRUG

SY-2101

SY-2101 will be administered per dose and schedule specified in arm description.

DRUG

Arsenic Trioxide

IV ATO will be administered per dose and schedule specified in arm description.

Trial Locations (8)

Weill Cornell Medical College, New York

UPMC Hillman Cancer Center, Pittsburgh

John Hopkins University, Baltimore

University of Alabama at Birmingham, Birmingham

University of Michigan, Ann Arbor

Northwestern Memorial Hospital, Chicago

University of Texas Southwestern Medical Center, Dallas

The University of Texas MD Anderson Cancer Center, Houston